Table 1:
Studies included in the systematic review and meta-analysis
| Author (year)† | Country | Study population | n | Age, yr, mean* | Baseline office BP,* mm Hg, mean ± SD | Brand of monitor and validation for pregnancy | No. of measurements/wk |
|---|---|---|---|---|---|---|---|
| Dalton et al. (1987)20 | UK | HDP | 10 | Range 28 to 39 |
136 ± 17/83 ± 8 | Dinamap 1846, not validated | 4 to 28 |
| Mooney et al. (1991)21 | UK | 1 or 2 high BP readings | 35 | NA | 139 ± 13/74 ± 10 | Dinamap 1846P, not validated | 10 |
| Naef et al. (1998)22 | US | HTN | 7 | NA | MAP 102 ± 10 | Vasoplex, not validated | 4 to 28 |
| Lo et al. (2002)23 | New Zealand | Normal | 101 | NA | 107 ± 8/66 ± 7 | Omron HEM-705CP, validated | 4 (1 d only) |
| Brown et al. (2004)24 | New Zealand | WCH | 66 | NA | 126/80 | Omron HEM-705CP, not validated | 6 |
| Rey et al. (2007)25 | Canada | Normal, HTN | 123 | Normal 31.4 HTN 32.7 |
127 ± 3/80 ± 2 | Aneroid, not validated | 3 to 7 |
| Rey et al. (2009)26 | Canada | HTN, WCH, PE | 159 | HTN 32.5 WCH 29.6 PE 32.2 |
NA | Aneroid, not validated | 6 to 14 |
| Chung et al. (2009)27 | UK | HDP | 21 | NA | NA | Microlife WatchBP, validated | 24 |
| BOSHI (2013, 2015, 2016)17–19 | Japan | Normal | 530 | 31.2 | Normal 108 ± 11/66 ± 9 HTN 119 ± 13/74 ± 9 |
Omron HEM-747IC, HEM7080IC, not validated | 7 |
| Denolle (2014)28 | France | Normal | 45 | 30 | 115 ± 11/65 ± 7 | Hestia Pharma D2, not validated | 36 |
| Tucker et al. (2017)29 | UK | High risk for PE | 161 | 31.0 | 117 ± 10/71 ± 9 | Microlife WatchBP, validated | 12 |
| Mikami et al. (2017)30 | Japan | Normal | 100 | 35.8 | 114 ± 10/68 ± 6 | Omron 7251G, not validated | 14 |
| Lan et al. (2017)31 | Australia | HTN | 37 | 33.4 | NA | Omron HEM-7200, not validated | 14 |
| Perry et al. (2018)32 | UK | HTN | 166 | 32.5 | NA | Microlife WatchBP, validated | 4 to 14 |
| Kalafat et al. (2018)33 | UK | HTN | 147 | 34 | 134 ± 3/88 ± 3 | Microlife WatchBP, validated | NA |
| Vestgaard et al. (2019)34 | Denmark | Normal | 103 | 32 | 115 ± 11/72 ± 7 | Microlife 3A Plus, validated | 18 |
| Vestgaard et al. (2019)35 | Denmark | Pre-existing diabetes mellitus | 222 | WCH: 33 HTN: 34 Normal: 32 |
WCH: 133 ± 10/87 ± 5 HTN: 130 ± 13/84 ± 10 Normal: 117 ± 9/74 ± 6 |
Microlife 3A Plus, validated | 18 |
| Pealing et al. (2019)36 | UK | HTN HDP |
154 | HTN: 35.9 GHTN: 33.4 |
HTN: 136.6 ± 13.8/85.9 ± 10.1 GHTN: 139.5 ± 13.1/86.9 ± 9.9 |
Microlife WatchBP, validated | 14 |
| Usuzaki et al. (2020)37 | Japan | Normal | 656 | 32.2 | 110.5 ± 10.8/63.8 ± 8.7 | Omron HEM-7080IC, not validated | 7 |
Note: BOSHI = Babies and Their Parents’ Longitudinal Observation in Suzuki Memorial Hospital on Intrauterine Period, BP = blood pressure, GHTN = gestational hypertension, HDP = hypertensive disorders of pregnancy, HTN = hypertension, MAP = mean arterial pressure, NA = not available, PE = preeclampsia, SD = standard deviation, WCH = white coat hypertension.
*
Except where indicated otherwise.
†
All studies were observational except Pealing and colleagues.36